arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Voyager Therapeutics, Inc.

VYGR
$2.87 ▼ -0.27 (-8.74%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
50 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

Voyager Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $173.8M
Dividend Yield
Revenue Growth -39.1%
Op. Margin None
ROIC -17.1%
FCF / Share $-0.43
Trailing P/E
Price / Book 1.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

50-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$3.17M
↓ -39.1%
Net Income Profit after all expenses
$-27.94M
↑ +9.9%
Operating Margin Operating profit as % of sales
-195.2%
↑ +14.7% 0th
FCF / Share Free cash flow per share
$-0.43
↑ +24.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns
14
Cash Quality
70

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 13 years · 50 quarters